Tags

Type your tag names separated by a space and hit enter

Formulation development and optimization: Encapsulated system of Atenolol and Glyburide.
Pak J Pharm Sci. 2016 Mar; 29(2):569-77.PJ

Abstract

PURPOSE

Objective of this study is to develop; tablet-in-a capsule system, to deliver Atenolol 25mg and Glyburide 5mg in the hard gelatin capsule. In order to improve patient compliance and reduce problems associated with complex therapeutic regimen Atenolol (cardio-selective beta-blocker) and Glyburide (anti-diabetic; sulfonylurea) are commonly, prescribed to the diabetic hypertensive patient. Metgod: In present work six different formulations of Atenolol (AF1-AF6) and Glyburide (GF1-GF6) were prepared by direct compression method using Avicel, Lactose DC, Crospovidone and Magnesium Stearate in different proportions and encapsulated in hard gelatin shells. Post compression parameters i.e. weight variation, diameter variation, thickness variation, hardness variation, % friability, disintegration, % drug release were determined at different pH 1.2, 4.5 and 6.8, and subjected to dissolution profile comparison through similarity factor (ƒ2).

RESULTS

Stability studies were performed and shelf lives were calculated by R-Gui Stab R console 2.15.2 and determined to be 15 and 27 months for Atenolol and Glyburide respectively. The percentage drug contents of Atenolol and Glyburide were estimated spectrophotometerically at 286 nm and 314.7 nm respectively. Formulations CF1-CF6 (encapsulated) were subjected to weight variation, disintegration and dissolution tests and subjected to model dependant analysis for dissolution studies. The simultaneous quantitation of Atenolol and Glyburide for content assay was done by HPLC method of analysis.

CONCLUSION

formulation CF6 is showing highest coefficient of correlation values for all models applied. So we can conclude that the proposed system can improve patient compliance by increasing the ease of administration of two drugs together.

Authors+Show Affiliations

Maboos M
Department of Pharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Yousuf RI
Department of Pharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
Shoaib MH
Department of Pharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.

MeSH

Administration, OralAdrenergic beta-1 Receptor AntagonistsAtenololCapsulesChemistry, PharmaceuticalChromatography, High Pressure LiquidDiffusionDrug CombinationsDrug StabilityExcipientsGlyburideHardnessHydrogen-Ion ConcentrationHypoglycemic AgentsKineticsModels, ChemicalSolubilitySpectrophotometry, UltravioletTabletsTechnology, Pharmaceutical

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

27087100

Citation

Maboos, Madiha, et al. "Formulation Development and Optimization: Encapsulated System of Atenolol and Glyburide." Pakistan Journal of Pharmaceutical Sciences, vol. 29, no. 2, 2016, pp. 569-77.
Maboos M, Yousuf RI, Shoaib MH. Formulation development and optimization: Encapsulated system of Atenolol and Glyburide. Pak J Pharm Sci. 2016;29(2):569-77.
Maboos, M., Yousuf, R. I., & Shoaib, M. H. (2016). Formulation development and optimization: Encapsulated system of Atenolol and Glyburide. Pakistan Journal of Pharmaceutical Sciences, 29(2), 569-77.
Maboos M, Yousuf RI, Shoaib MH. Formulation Development and Optimization: Encapsulated System of Atenolol and Glyburide. Pak J Pharm Sci. 2016;29(2):569-77. PubMed PMID: 27087100.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Formulation development and optimization: Encapsulated system of Atenolol and Glyburide. AU - Maboos,Madiha, AU - Yousuf,Rabia Ismail, AU - Shoaib,Muhammad Harris, PY - 2016/4/19/entrez PY - 2016/4/19/pubmed PY - 2016/7/1/medline SP - 569 EP - 77 JF - Pakistan journal of pharmaceutical sciences JO - Pak J Pharm Sci VL - 29 IS - 2 N2 - PURPOSE: Objective of this study is to develop; tablet-in-a capsule system, to deliver Atenolol 25mg and Glyburide 5mg in the hard gelatin capsule. In order to improve patient compliance and reduce problems associated with complex therapeutic regimen Atenolol (cardio-selective beta-blocker) and Glyburide (anti-diabetic; sulfonylurea) are commonly, prescribed to the diabetic hypertensive patient. Metgod: In present work six different formulations of Atenolol (AF1-AF6) and Glyburide (GF1-GF6) were prepared by direct compression method using Avicel, Lactose DC, Crospovidone and Magnesium Stearate in different proportions and encapsulated in hard gelatin shells. Post compression parameters i.e. weight variation, diameter variation, thickness variation, hardness variation, % friability, disintegration, % drug release were determined at different pH 1.2, 4.5 and 6.8, and subjected to dissolution profile comparison through similarity factor (ƒ2). RESULTS: Stability studies were performed and shelf lives were calculated by R-Gui Stab R console 2.15.2 and determined to be 15 and 27 months for Atenolol and Glyburide respectively. The percentage drug contents of Atenolol and Glyburide were estimated spectrophotometerically at 286 nm and 314.7 nm respectively. Formulations CF1-CF6 (encapsulated) were subjected to weight variation, disintegration and dissolution tests and subjected to model dependant analysis for dissolution studies. The simultaneous quantitation of Atenolol and Glyburide for content assay was done by HPLC method of analysis. CONCLUSION: formulation CF6 is showing highest coefficient of correlation values for all models applied. So we can conclude that the proposed system can improve patient compliance by increasing the ease of administration of two drugs together. SN - 1011-601X UR - https://www.unboundmedicine.com/medline/citation/27087100/Formulation_development_and_optimization:_Encapsulated_system_of_Atenolol_and_Glyburide_ DB - PRIME DP - Unbound Medicine ER -